| SFDA Approved Use |
Macitentan, as monotherapy or in combination, is indicated for the long-term treatment of pulmonary arterial hypertension (PAH) in adult patients of WHO Functional Class (FC) II to III.
Efficacy has been shown in a PAH population including idiopathic and heritable PAH, PAH associated with connective tissue disorders, and PAH associated with corrected simple congenital heart disease |
|---|
An official government website affiliated with the Government of the Kingdom of Saudi Arabia.
Thu 25 Jun 2026
Beta version
Official Saudi government website domains end with gov.sa
All official websites of government entities in the Kingdom of Saudi Arabia end with.gov.sa.
Government websites use the protocol. HTTPS for encryption and security.
All official websites of government entities in the Kingdom of Saudi Arabia end with.gov.sa.
Comments and Suggestions
For any inquiries or comments about the government services, please fill in the required information.